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SUMMARY 
 
In response to various inflammatory stimuli, neutrophils secrete neutrophil extracellular traps (NETs), 
web-like meshworks of DNA, histones and granular components forming supplementary scaffolds in 
venous and arterial thrombi. Isolated DNA and histones are known to promote thrombus formation and 
render fibrin clots more resistant to mechanical forces and tissue-type plasminogen activator (tPA)-
induced enzymatic digestion. The present study extends these earlier observations to a physiologically 
more relevant environment including plasma clots and NET-forming neutrophils. A range of techniques 
was employed including imaging (scanning electron microscopy (SEM), confocal laser microscopy, and 
photoscanning of macroscopic lysis fronts), clot permeability measurements, turbidimetric lysis and 
enzyme inactivation assays. Addition of DNA and histones increased the median fiber diameter of 
plasma clots formed with 16 nM thrombin from 108 to 121 and 119 nm, respectively, and decreased 
their permeability constant from 6.4 to 3.1 and 3.7×10-9 cm2. Histones effectively protected thrombin 
from antithrombin-induced inactivation, while DNA inhibited plasminogen activation on the surface of 
plasma clots and their plasmin-induced resolution by 20 and 40%, respectively. DNA and histones, as 
well as NETs secreted by phorbol-myristate-acetate-activated neutrophils, slowed down the tPA-driven 
lysis of plasma clots and the latter effect could be reversed by the addition of DNase (streptodornase). 
SEM images taken after complete digestion of fibrin in NET-containing plasma clots evidenced retained 
NET scaffold that was absent in DNase-treated clots. Our results show that DNA and histones alter the 
fibrin architecture in plasma clots, while NETs contribute to a decreased lytic susceptibility that can be 
overcome by DNase. 
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Extra table 
What is known on this topic: 
 In response to inflammatory stimuli neutrophils are able to expel their granular and 
nuclear components to form NETs that capture a variety of microbes. 
 NETs also entrap and activate platelets, and promote both pathways of the 
coagulation cascade, contributing to an increased risk of venous and arterial 
thrombosis. 
 Isolated DNA and histones render fibrin clots more resistant to mechanical forces 
and tPA-induced enzymatic degradation. 
What this paper adds: 
 DNA and histones increase the fiber thickness and decrease the permeability of 
fibrin in plasma clots. 
 DNA alone inhibits plasmin-driven lysis of plasma clots.  
 NETs formed by activated neutrophils hinder the tPA-induced resolution of plasma 
clots.  
 Provides a rationale for NET-targeted strategies to improve thrombolysis. 
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INTRODUCTION 
 
Neutrophil extracellular traps (NETs) composed of DNA, histones and other associated proteins 
secreted from activated neutrophils represent an evolutionarily conserved means of antimicrobial 
defence (1). Nevertheless, besides their protectiveness at the site of infection, NETs have been 
identified as key factors in the pathogenesis of numerous diseases (reviewed in (2)), including venous 
(reviewed in (3)) and arterial (4) thrombosis. In the course of NETosis (5), DNA and histones -the 
major components of NETs- are released from activated neutrophils together with other proteins (e.g. 
neutrophil elastase), creating web-like structures (1) capable of trapping not only various microbes, but 
also blood cells, platelets and proteins involved in coagulation. Histones, the most abundant proteins in 
NETs (6), exert clear pro-thrombotic effects by influencing cellular and protein components of the 
haemostatic system. They induce activation of platelets (7) and endothelial cells (8), inhibit activated 
protein C-mediated negative feedback of the coagulation cascade (9), and directly support thrombin 
activation (10). DNA, on the other hand, enhances the activity of factor XII (11), while neutrophil 
elastase and other proteases degrade inhibitors of the coagulation cascade (reviewed in (12)).  
Considering this range of effects, and the fact that NETs are recognized as a supplementary scaffold of 
thrombi (besides fibrin) (13), the need for a thorough assessment of their influence on thrombolysis 
seems compelling. Our previous studies indicate that DNA and histones exert marked effects on the 
structural and mechanical parameters of fibrin clots, and render them more resistant to tissue-type 
plasminogen activator (tPA)-driven lysis (14). However, these investigations need to be extended to a 
plasma environment and explored using neutrophil-derived NETs.  
 
MATERIALS AND METHODS 
 
Proteins and reagents 
 
Calf thymus DNA, streptokinase and fibrinogen (plasminogen-depleted) were from Calbiochem, 
LaJolla, CA, USA. Plasmin was generated using plasminogen (isolated from human plasma (15)) 
activated by streptokinase at 172 IU/mg zymogen. For plasmin inactivation assays, 40 M plasminogen 
was activated by 70 nM tPA (Boehringer Ingelheim, Ingelheim am Rhein, Germany) at 37 °C for 25 
min. Plasmin concentrations were calculated as described in (16). HIIIS (histone IIIS from calf thymus), 
PMA (phorbol 12-myristate 13-acetate), BSA (bovine serum albumin), HSA (human serum albumin) 
and mouse anti-human H3 antibody (SAB4200591) were obtained from Sigma-Aldrich, Budapest, 
Hungary. Thrombin (Serva Electrophoresis GmbH, Heidelberg, Germany) was purified as described in 
(17). Antithrombin and Spectrozyme-PL (H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroanilide) were 
purchased from American Diagnostica, Pfungstadt, Germany. S-2251 (val-leu-lys-p-nitroanilide) was 
from Chromogenix SpA, Milano, Italy. Heparin was acquired from Wockhardt, Wrexham, UK. 
Activated protein C (APC, Xigris) was from Eli Lilley Inc, Indianapolis, USA. Streptodornase (08/230 
the WHO 2nd International Standard for Streptodornase, a mixture of streptokinase and streptodornase) 
and1-protease inhibitor (NIBSC preparation code 05/150) were obtained from NIBSC, South Mimms, 
UK. 2-plasmin inhibitor was purchased from Calbiochem. Alexa Fluor® 546-conjugated fibrinogen 
and goat anti-mouse antibody, Alexa Fluor ®488-conjugated goat anti-rabbit antibody and fluorescent 
nucleic acid dye (TOTO-3®) were from Invitrogen Life Technologies, Budapest, Hungary. Rabbit anti-
human citrullinated H3 (ab5103) was purchased from Abcam (Cambridge, UK). tPA was modified to 
express a C-terminal fusion of Yellow Fluorescent Protein (YFP) using pFastBac-tPA (and derivatives) 
as previously described (18). Citrated, fresh frozen plasma (fibrinogen concentration: 4.16 g/l) and 
buffy coat fraction of human blood were obtained from the Hungarian Blood Supply Service, Budapest, 
Hungary. If not otherwise indicated, plasma was recalcified with 12.5 mM CaCl2 immediately before 
measurements. Isolation of neutrophil granulocytes from buffy coat and extraction of DNA were carried 
out as described in (14,19). Neutrophil DNA was used for confocal studies; other assays were carried 
out using calf thymus DNA. If not otherwise indicated, experiments were performed using HEPES 
buffered saline (HBS: 10 mM HEPES buffer pH 7.4 containing 150 mM NaCl) ± additives.  
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Scanning electron microscope (SEM) and confocal laser scanning microscope (LSM) imaging  
 
Plasma clots were prepared from mixtures of 2-fold diluted recalcified human plasma, and various 
concentrations of DNA and/or HIIIS and clotted with 16 nM thrombin at 37 °C for 60 min. Clots were 
washed 7 times with distilled water at 4 °C for 5 min. 
Granulocytes at 5×104/l (in 600 l phosphate-buffered saline pH 7.4, PBS: 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4, 137 mM NaCl, 2.7 mM KCl and 5 mM glucose) were pipetted into culture plate wells 
containing cover slips with a diameter of 6 mm at the bottom. Cells were activated with 50-100 nM 
PMA for 4 hours at 37 °C. After the incubation, the fluid phase was withdrawn. In certain cases, cover 
slips were thereafter dipped in a mixture of 10 nM thrombin and 6 M fibrinogen.  
For SEM imaging, samples were treated and examined with scanning electron microscope EVO40 (Carl 
Zeiss GmbH, Oberkochen, Germany) and the images were analyzed to determine the diameter of the 
fibrin fibers as described previously (14,20).  
For LSM examination, samples were fixed and immunostained according to a protocol modified from 
(21), using anti-citrullinated H3 and anti-H3 antibodies, and fluorescent nucleic acid dye TOTO-3®. 
Confocal fluorescent images were taken using a Zeiss LSM710 confocal laser scanning microscope 
(Carl Zeiss, Jena, Germany). 
Clot permeability assays 
Fibrinogen at 8 M or plasma supplemented with 20 mM CaCl2 ± additives (50 g/ml DNA and/or 250 
g/ml HIIIS) were clotted with 16 nM thrombin in plastic pipette tips. After 70 min of incubation at 
37 °C, HBS was permeated through the clots. Pressure was kept constant by maintaining a fixed head 
volume.  
KS (permeability coefficient) was calculated from the equation . .. .S
Q LK
t A P
  (22), where Q = permeated 
volume of buffer (cm3);  = viscosity of buffer (10-2 poise = 10-7 N s cm-2); L = clot length (1.5 cm for 
fibrin clots, 1.7 cm for plasma clots); A = average cross-sectional area of the clot (0.102 cm2 for fibrin 
clots, 0.057 cm2 for plasma clots); t = time (s); ΔP = pressure drop (0.209 N cm-2 for fibrin clots, 0.056 
N cm-2  for plasma clots). 
 
Thrombin inactivation assays 
 
Mixtures of antithrombin, thrombin and various concentrations of HIIIS and DNA in the presence or 
absence of heparin were incubated at room temperature. After various incubation times, clotting was 
initiated by the addition of fibrinogen. Clotting time was measured with a coagulometer KC-1A 
(Amelung, Lemgo, Germany) at 37 °C.  
Plasminogen activation assay 
In 96-well microtiter plates, 2-fold diluted recalcified plasma ± additives (50 g/ml DNA and/or 250 
g/ml HIIIS) was clotted with 16 nM thrombin in a volume of 80 l. After 45 min at 37 °C 60 l of 
28 nM tPA and 0.6 mM Spectrozyme-PL were placed on the surface of the clot. The forming plasmin 
generated p-nitroaniline, the absorbance of which was continuously recorded at 405 nm (A405) with 
Zenith 200rt spectrophotometer (Anthos Labtec Instruments GmbH, Salzburg, Austria). The apparent 
maximal initial rate of plasminogen activation in the reactive layer of fibrin (Vapp) was calculated from 
A405 values as described in (23).   
Fibrinolytic assays                                                                                                                 
tPA-driven lysis of plasma clots was studied in 96-well microtiter plates. Two-fold diluted recalcified 
plasma was mixed with 16 nM thrombin, 3.75 M plasminogen, and various concentrations of DNA 
and HIIIS. In another set of experiments, instead of pure DNA and histones, 5×103/l granulocytes (in 
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HBS containing 5 mM glucose) ± 100 nM PMA were incorporated into two-fold diluted recalcified 
plasma isolated from buffy coat containing 3.75 M plasminogen. Following 60 min clotting, lysis was 
initiated by addition of 200 nM tPA to the clot surface. In the case of experiments with neutrophils, the 
time for clotting was prolonged up to 240 min to allow for NET formation, and tPA was supplemented 
with various concentrations of APC, streptokinase, and streptodornase to initiate lysis. Clot formation 
and dissolution was followed by measuring the light absorbance at 340 nm at 37 °C with a Zenyth 200rt 
microplate spectrophotometer. For adequate comparison of lytic rates from measurements, in which 
different maximum turbidity values were reached despite the identical quantities of fibrin, the 
absorbance values were normalized as (A-A0)/Amax where Amax is the maximal- and A0 is the final 
absorbance at 340 nm after complete lysis. The time needed to reduce the turbidity of the clot to a given 
fraction of the maximal value (T0.5 to reach 0.5Amax, T0.1 to reach 0.1Amax) was used as a quantitative 
parameter of fibrinolytic activity.  
For LSM imaging of lysis, clots were prepared from 2-fold diluted recalcified plasma supplemented 
with 90 nM Alexa Fluor® 546-conjugated fibrinogen and 1.5 M plasminogen, clotted with 16 nM 
thrombin for 30 min at room temperature in sterile, uncoated IBIDI VI 0.4 -slides (Ibidi GmbH, 
Martinsried, Germany). In certain cases, 45 g/ml DNA and/or 280 g/ml HIIIS were also present in 
the mixture. Thereafter, 85 nM tPA-YFP (supplemented with 3 M plasminogen) was added to the edge 
of the clot and the fluorescence was monitored as described in (23). 
Plasmin-induced lysis was also examined in IBIDI VI 0.4 -slides. Two-fold diluted recalcified plasma 
containing 0/50 g/ml DNA and/or 250 g/ml HIIIS were mixed with 16 nM thrombin. The mixtures 
were quickly pipetted into the 30 l channnels of IBIDI slides, and incubated at 37 °C for 30 min. Lysis 
was initiated by the addition of 60 l of 5 M plasmin introduced to the opening of the channels and 
followed by time lapse photoscanning of the transparent fluid/opaque clot boundary. 
Plasmin inactivation assays 
The effects of DNA ± histones on the interactions of isolated plasma inhibitors and plasmin were 
evaluated at 37 C by following slow binding inhibition kinetics of 0.2 nM plasmin with a range of 2-
plasmin inhibitor concentrations in HBS containing 1 mg/ml fibrinogen and 500 µM tranexamic acid to 
mimic fibrin and slow down kinetics of plasmin-2-plasmin inhibitor complex formation (24).  
Similarly, slow binding inhibition of 0.4 nM plasmin by a range of 1-protease inhibitor concentrations 
was studied in HBS containing 1 mg/ml HSA. Plasmin activity was monitored by following the 
hydrolysis of 0.3 mM S-2251. Kinetics were studied for up to 2.5 hours in the presence of no further 
additives or with 50 g/ml of DNA or HIIIS. Association rate constants were calculated from plots of 
kobs versus inhibitor concentrations, after fitting to the equation for irreversible binding of plasmin and 
inhibitor (2-plasmin inhibitor or 1-protease inhibitor), A405=Ao+(vo/kobs)(1-exp(-kobst), where Ao is 
initial absorbance, kobs is the apparent rate constant for complex formation and vo is the initial rate of 
plasmin activity on S-2251 (24). To study the effect of DNA on antithrombin-plasmin interaction, 2.5 
nM plasmin and 0.7 M antithrombin in HBS containing 1 mg/ml BSA were mixed with a range of 
DNA concentrations, and plasmin activity was monitored by following the hydrolysis of 0.05 mM 
Spectrozyme-PL. 
 
Statistical analysis 
 
The distribution of the data on fiber diameter was analyzed using an algorithm described previously: 
theoretical distributions were fitted to the empirical data sets and compared using Kuiper’s test and 
Monte Carlo simulation procedures running under the Matlab 8.1.0.604 (R2013a) (The Mathworks, 
Natick, MA) (17,20). The statistical evaluation of other experimental measurements in this report was 
performed with Kolmogorov-Smirnov test (Statistical Toolbox 7.3 of Matlab). 
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RESULTS 
 
Structural studies 
 
If isolated neutrophils were activated for 4 h by PMA, well-defined NET structures could be observed 
with SEM (Fig. 1A and 1B) as a meshwork of fine fibers (approximately 10 nm diameter) decorated 
with protein aggregates and cell debris. LSM analysis confirmed the presence of the NETosis-hallmark 
citrullinated histones (25) in the nucleus of the activated neutrophils, as well as in the extracellular 
space of immunostained samples (Fig. 1E). If NET formation was induced in a fibrin environment, 
fibrin fibers were around 100 nm in diameter and could be clearly identified in fibrin-rich regions of 
SEM images (Fig. 1C and D), however, in heterogeneous regions of the clot, the distinction between 
NET and fibrin was not always straightforward. For reliable quantitative analysis of the fibrin fiber 
diameter, this meshwork was modelled in a simplified, more homogeneous experimental setup. DNA 
and/or HIIIS were added to recalcified plasma clotted with thrombin at concentrations matching the 
values used for lysis (16 nM) and thrombin inactivation assays (60 nM). Addition of DNA, HIIIS or 
their mixture resulted in thicker fibers at 16 nM thrombin, while at the higher thrombin concentration 
HIIIS caused a slight, although statistically significant reduction of fiber diameter. DNA alone had 
similar effects in the two systems, leading to formation of thicker fibers (Table 1).  
Since thrombin concentration is a major determinant of fiber thickness (18), plasma inhibitors affecting 
thrombin activity might play a role in the observed changes in fibrin structure. To test this possibility, 
the influence of histones/DNA on the inactivation of thrombin was studied by detecting residual 
thrombin activity after exposure to its main plasma inhibitor antithrombin. HIIIS proved to be very 
effective in protecting thrombin from inactivation regardless of the presence of heparin. Increasing 
concentrations of DNA partially attenuated histone-mediated protection of thrombin in the presence of 
physiological antithrombin concentration (2.5 µM) (Suppl. Fig. 1S).      
Fiber diameter values provide indirect information about the average pore size of the fibrin network 
(thicker fibers are associated with larger pores) (26,27), which can be validated by measurement of clot 
permeability, a physiologically more relevant indicator of pore size (28). As Table 2 shows, HIIIS 
reduced the permeability constant in plasma clots by almost 50%, while it increased permeability 
approximately 4-fold in fibrin clots, which could be partially opposed by the addition of DNA. DNA 
alone reduced the permeability constant in both fibrin and plasma clots by 27 and 51%, respectively.  
 
tPA-dependent plasminogen activation and lysis of plasma clots containing DNA and HIIIS  
 
In view of the known impact of fibrin structure on its lytic susceptibility (reviewed in 29) DNA and 
HIIIS could be expected to affect the sequential steps of fibrinolysis (plasminogen activation, clot 
digestion). To assess their effects on plasminogen activation, DNA and HIIIS were incorporated into 
plasma clots and a chromogenic plasmin substrate (Spectrozyme-PL) was added to the clot surface 
together with tPA (Fig. 2). While DNA alone reduced the rate of plasmin formation by 20%, histones 
enhanced plasmin generation, independently of the presence of DNA (Fig. 2, inset).  
To study the effects of DNA and HIIIS on plasmin-induced lysis, plasma clots were prepared in 
microchannels and lysis was followed by time-lapse photoscanning of the lytic front. Incorporation of 
DNA in the clots reduced the distance run by the lysis front at 60 min by 40%. HIIIS alone had no 
significant effect, while it opposed DNA effects when added in combination (Fig. 3). A possible 
explanation for the effect of DNA in this assay might be the DNA-mediated enhancement of plasmin 
inactivation. This was tested by measurements of plasmin interactions with physiologically relevant 
antiproteases (2-plasmin inhibitor, 1-protease inhibitor, antithrombin). Neither DNA nor HIIIS had 
significant effect on the apparent rate constants of plasmin inactivation by the tested inhibitors (Suppl. 
Fig. 2S and 3S).   
The microscale pattern of tPA-induced plasma clot lysis was examined with LSM. Plasma clots were 
supplemented with fluorescent fibrinogen, and the movement of the lysis front with accumulated 
fluorescent tPA-YFP was measured for 30 min (Fig. 4). DNA and histones alone had non-significant 
effects on the tPA-front penetration, however, when added simultaneously, the final run distance of the 
lysis front was reduced by approximately 25%. Hindered lysis was accompanied by subtle changes in 
the microscopic pattern of the clot-tPA interface: unlike the rough granular surface seen in clots without 
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any additives, a fine granular structure showing less aggregate formation could be observed in clots 
formed in the presence of DNA and HIIIS (Fig. 4A and D). Delayed lysis was also observed in the final 
stages of the turbidimetric assay of plasma clots containing DNA and HIIIS (Fig. 5). Closer analysis of 
lysis curves revealed that DNA and histones prolonged the average time elapsed until 90% clot lysis 
(T0.1) when added separately or together, while the time needed for 50% lysis (T0.5) remained largely 
unchanged (Fig. 5, inset). 
 
Lysis of plasma clots containing activated neutrophils 
 
PMA-activated neutrophils incorporated within plasma clots may be a better approach to the in vivo 
situation and their effects on clot lysis were studied in another set of turbidimetric assays. The presence 
of NETs generated by granulocytes at physiological cell count incorporated in the clots increased T0.1 
values by a factor of 2.11±0.23 (n=14 from 3 independent experiments, p<0.05), while T0.5 was only 
moderately increased by a factor of 1.25±0.26 (n=14 from 3 independent experiments, p<0.05) (Suppl. 
Fig. 4S). To investigate which NET components were responsible for the delayed lysis, tPA was 
supplemented with enzymes capable of DNA or histone degradation. Streptococci produce a DNase 
(streptodornase) in addition to the plasminogen activator protein streptokinase, while APC is known to 
digest histones (30). Streptodornase was able to enhance the lytic potency of streptokinase in plasma 
clots containing NET-producing neutrophils (Fig. 6 and Table 3), while in cell-free plasma clots this 
effect was absent (data not shown). Addition of APC to the fibrinolysis cocktail had no significant 
effect. Macroscopic inspection of clot remnants after 200 min lysis showed remarkable differences: 
while most wells contained a fine, web-like aggregate that remained unlysed, these were absent from 
the wells containing streptodornase (Fig. 6, inset). SEM images of aggregates revealed intact NET 
structures retained after the complete digestion of fibrin by plasmin (Fig. 6, inset). 
 
DISCUSSION 
 
Although the circulating cell-free DNA level is generally low in blood (50-100 ng/ml) (31), under 
certain pathological conditions (e.g. malignancy), this can rise up to 0.5-5 g/ml (32), while studies in 
baboon sepsis models evidence circulating histone levels up to 70 g/ml (30). In addition to these 
baseline values, thrombosis-associated inflammatory signals may induce migration of granulocytes into 
thrombi (33), where expulsion of nuclear contents through necrosis or NETosis could lead to higher 
local concentrations. The possibility for extreme focal accumulation of NET components is exemplified 
by the micromolar concentration of neutrophil elastase measured in the immediate pericellular zone of 
activated neutrophils (34), and it is supported by the intense DNA and histone staining observed in 
leukocyte-rich thrombi (14). Therefore, the range applied in this study (5-50 g/ml for DNA and 0.5-
280 g/ml for histones) seems relevant to reflect their availability following clot formation in an 
inflammatory environment. 
Regardless of their sources –dead cells in the necrotic debris of eroded atherosclerotique plaques, or 
neutrophils forming NETs as a response to intravascular inflammatory signals– DNA and histones are 
most likely to appear as complexes in the circulation (35). Nevertheless, mounting data suggest that, 
under certain conditions, histones might become separated from DNA. Previous analysis has shown that 
less H3 and H4 histones are found in NETs than in chromatin (6), and that citrullination displaces H1 
from chromatin in certain cells (36). In addition, our previous immunohistochemistry studies on ex vivo 
arterial thrombi reveal clot regions where DNA and histones are not co-localized (14). Taken together, 
these data provide a basis to assess the effect of isolated DNA and histones as well as NETs and other 
DNA-histone complexes on the structure and lysis of clots.  
In our previous and present studies, DNA and HIIIS (from calf thymus) were used for that purpose, 
however, this imposes limitations on the in vivo extrapolation from the data obtained. For instance, 
citrullination of histones, which is a prominent hallmark of NETosis ((25) and Fig. 1E), may lead to 
alterations of their effects on clot structure and lysis. Therefore, we have expanded our studies with the 
incorporation of PMA-activated neutrophils into plasma clots to gain physiologically more relevant 
information on the fibrinolytic effects of NETs.       
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Effects of DNA and HIIIS on clot structure 
 
Clot structure, a major determinant of lytic susceptibility, is influenced by a variety of enzymatic (e.g. 
thrombin concentration) (18), cellular (e.g. red blood cells) (37) and mechanical (e.g. shear stress) (17) 
factors. According to our studies, DNA and histones further increase the already existing complexity.  
In plasma clots formed with 16 nM thrombin, the median fiber diameter increased in the presence of the 
examined additives, and the strongest effect was seen when DNA and histones were added in 
combination (Table 1). These results are in agreement with the tendencies observed in fibrin clots (14). 
Given that the apparent thrombin and fibrinogen concentrations were identical in the two systems (fibrin 
and plasma clots), this finding supports the notion that DNA and histones disrupt the spatial 
arrangement of monomer blocks and protofibrils, as suggested by small-angle X-ray scattering data (14). 
The essentially minor effect of histones in plasma clots formed with 60 nM thrombin with a slight 
opposite, decreasing trend of diameter values, however, suggests that this is not the only mechanism 
through which histones influence fiber thickness. Thrombin inactivation assays (Suppl. Fig. 1S) 
revealed that histones are able to protect thrombin from inhibition by antithrombin (in agreement with 
(9), where histones were found to shorten clotting times in normal plasma), in support of the previous 
findings and adding a new mechanism emphasizing their procoagulant role (7-10). Given that increasing 
thrombin concentrations result in formation of thinner fibers in plasma clots (24), the final fibrin 
structure in the presence of histones may reflect the net result of two opposing tendencies (disruption of 
protofibril arrangement versus protection of thrombin from inactivation). 
Fiber diameter and clot pore area are considered to be positively correlated (26,27). Permeability 
coefficients measured in fibrin clots supported this correlation; in the present study we established that 
the previously reported increase in median fiber diameter (14) was accompanied by a higher value of 
the permeability constant implying larger average pore areas in clots containing histones ± DNA (Table 
2). However, DNA alone decreased permeability, despite the increased fiber diameters, which may be 
attributed to its pore-filling property suggested by Fig. 1 C. In the more complex plasma environment, 
the size of pores estimated from permeation studies did not strictly follow the trend predicted by fiber 
thickness (Tables 1 and 2). These discrepancies may point out the importance of interactions between 
DNA/histones and other components of plasma, which remain to be further investigated. 
 
Effects of DNA, HIIIS and NETs on clot lysis 
 
Fibrinolysis is a result of sequential activation of plasminogen and plasmin-catalyzed cleavage of fibrin 
fibers. On the surface of clots both steps are affected by the structural characteristics (e.g. fiber 
thickness and permeability) of fibrin, and in vivo this scenario can be further complicated by a variety of 
blood-borne factors (reviewed in (29)). With our experiments we modelled the fibrinolytic events 
relevant to therapeutic thrombolysis applying tPA concentrations that have been reported in plasma of 
patients treated for acute myocardial infarction (150 nM) or deep vein thrombosis (300 nM) (38,39). 
The changes observed in clot structure in the presence of DNA and HIIIS were accompanied by 
alterations of clot lysis. According to LSM (Fig. 4), DNA and histones disturbed the pattern of tPA-
induced lysis, and their combination resulted in a 25% decrease in the average run distance of tPA 
fronts (despite the enhanced velocity of plasmin formation on the clot surface shown in Fig. 2). These 
microscale data were in line with the turbidimetric assay, in which DNA and HIIIS prolonged T0.1 by 
approximately 15% while T0.5 remained essentially unchanged (Fig. 5, inset). This is in good 
agreement with time lapse images of lysing fibrin clots containing DNA/histones showing that early 
fibrinolysis is unaffected but complete clot breakdown is delayed (14). Studies using isothermal titration 
calorimetry have previously shown interactions between isolated DNA/HIIIS and large FDPs 
(molecular weight > 150 kDa) (14) providing a rationale for the retardation of the late phase of clot lysis.  
When lysis was initiated with plasmin, histones ± DNA had negligible effects on the macroscopic lytic 
front movement (Fig. 3), whereas DNA alone hindered lysis. Since in our assays DNA failed to 
potentiate inhibition of plasmin by its major plasma inhibitors (Suppl. Fig. 2S and 3S), its anti-
fibrinolytic effect might be explained by blocking plasmin binding to fibrin as shown in (40), where 
double stranded DNA at 1-20 g/ml inhibited plasmin-induced lysis of pure fibrin clots without 
substantially affecting the binding kinetics of plasmin to 2-plasmin inhibitor. In light of its inhibitory 
effects on both tPA- or plasmin-mediated lysis and the hindered tPA-induced plasminogen activation on 
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the clot surface (Fig. 2), a definite anti-fibrinolytic role can be attributed to DNA in a plasma 
environment. 
SEM and LSM confirmed that PMA-activated neutrophils produced NETs in our system (Fig. 1), and 
their incorporation in plasma clots resulted in a two-fold increase of T0.1 in comparison with clots 
containing non-activated cells. However, since the extent of lysis prolongation exceeds the effect seen 
with the combination of isolated DNA and histones, additional factors may also play a role in delayed 
fibrinolysis observed in this experimental setup. For example, peptidyl-arginyl-deiminase 4, the 
intracellular trigger of NET formation (25), has been shown to modify antithrombin and fibrinogen 
(41,42) in addition to histones, with possible lytic consequences. Besides its procoagulant effects 
mentioned in the Introduction section, NET-bound neutrophil elastase could be expected to exert a 
profibrinolytic activity, due to (I) degradation of 2-plasmin inhibitor (43), (II) conversion of 
plasminogen to the more readily activatable miniplasminogen, and (III) its direct fibrinolytic activity 
(44). Accordingly, pure fibrin containing PMA-activated neutrophils spontaneously lysed within 3-4 h 
indicating the release of neutrophil elastase as a part of NET-formation (data not shown). However, in a 
plasma environment rich in antiproteases, the overall effect of NETs on lysis was inhibitory despite the 
presence of neutrophil elastase (Suppl. Fig. 4S), underlining the significance of DNA in lytic resistance. 
 
Clinical perspective 
 
Besides the administration of tPA in cardio- and cerebrovascular diseases (45,46), direct plasmin 
application has been recently proposed as a safe thrombolytic method (47). Both strategies are targeting 
the fibrin meshwork, however, in vivo thrombi may contain NETs serving as supplementary scaffold 
(reviewed in 13), and histones/DNA may also accumulate in clots in a NETosis-independent manner 
(e.g. necrosis within atherosclerotic plaques). According to our current study, DNA alone hinders 
plasmin-mediated clot digestion, while DNA, histones, and NETs render plasma clots more resistant to 
lysis induced by therapeutic concentrations of tPA. APC, which digests histones in purified systems 
(30), failed to shorten lysis times in plasma clots containing NETs when combined with tPA (Table 3). 
This may be explained by reduced activity of APC on NET-bound histones (7), and that protease 
treatment leaves NET integrity intact. In contrast, addition of streptodornase –known to disrupt NETs 
(48)– accelerated clot degradation (Table 3), showing that NETs are also effectively degraded by the 
enzyme in a plasma clot environment (Fig. 6, inset). 
Previous work examining lysis of whole blood clots (49), and our investigations carried out with fibrin 
clots (14) (both using DNase I), as well as our present studies using plasma clots and streptodornase 
suggest that more efficient thrombolysis might result from combinations of fibrinolytic agents and 
enzymes able to digest DNA. Additional advantage of such an approach stems from the finding that 
plasmin enhances the effectiveness of DNases (50) and evidence from nature that some streptococci 
have increased their pathogenicity by co-evolving the plasminogen activator, streptokinase, and a 
DNase, streptodornase, to overcome host defences. Nevertheless, in vivo lysis models are required to 
decide whether these findings can be translated into actual clinical benefits.  
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FIGURE LEGENDS 
 
Fig. 1 SEM and LSM images of NETs produced by PMA-activated neutrophil granulocytes. A-
B: Web-like structures entrapping cells and cell-derived debris following 4 h activation of isolated 
neutrophil leukocytes by 50 nM PMA. C-D: NETs in a fibrin-rich environment (following PMA 
activation neutrophils were coated with a mixture of 10 nM thrombin and 6 M fibrinogen). The 
thicker, coarse fibrin (C: in the foreground, D: to the right) merges with the fine structure of NETs (C: 
in the background, partially filling the pores of fibrin, D: left bottom corner). Scale bar=1 m (A-D). 
E: LSM image of neutrophils activated in the same way as in panel A. The extracellular regions show 
DNA staining colocalized with citrullinated (citH3) and/or unmodified histone H3 (H3). Citrullination 
is also visible intracellularly. Scale bar=20 m.  
 
Fig. 2 tPA-induced plasminogen activation on the clot surface. Plasma clots containing 
plasminogen and the indicated additives were prepared and thereafter tPA and the plasmin substrate 
Spectrozyme-PL were added. The absorbance of the liberated p-nitroaniline was continuously 
measured at 405 nm (A405), and plotted against time squared. The figure shows mean values of eight 
measurements from a representative experiment. Inset: apparent maximal activation rates (Vapp) were 
calculated using the equation A405=0.5k1Vappt2 , where  is the extinction coefficient of p-nitroaniline, 
k1 is the turn-over number of plasmin on Spectrozyme-PL, kcat and [tPA] are the catalytic constant for 
plasminogen activation and the concentration of tPA in the reactive layer on the surface of fibrin, 
respectively. The term Vapp = kcat[tPA] is equivalent to the apparent maximal rate of plasminogen 
activation in the reactive layer of fibrin and was determined from linear regression according to the 
above mentioned equation (23). Mean values and standard deviation presented here are calculated 
from mean values of 3 independent experiments with 6-8 replicates each. Asterisk indicates a 
difference significant at p<0.05 in comparison to control. 
 
Fig. 3 Plasmin-induced lysis of clots. Two-fold diluted recalcified plasma mixed with 16 nM 
thrombin, and additives was injected in 0.4 mm high channels of microslides (IBIDI™) through the 
upper orifice, and 5 M plasmin was applied through the lower orifice after 60 min of clotting. A: 
initial stage. B: lysis fronts in the same microslide after 60 min. Additives (from left to right): none, 50 
g/ml DNA, 250 g/ml HIIIS, 50 g/ml DNA+250 g/ml HIIIS. C: Lysis front movement was 
registered every 15 min by photoscanning the samples and measured mm values of 60 min lysis front 
(opaque clot/transparent fluid interface) movement were normalized for the distance of the two centres 
of orifices (13 mm) to give relative units (RU). Mean values and standard deviation of at least 7 
measured values from 3 independent experiments are shown. Asterisk indicates a difference 
significant at p<0.05 in comparison to control.  
Fig. 4 Penetration of tissue plasminogen activator (tPA)-YFP into clots in the course of lysis. 
Clots were prepared from human plasma containing Alexa546-labeled fibrinogen, plasminogen and the 
indicated additives. After 30-min clotting tPA-YFP and plasminogen were added to the edge of the 
clot and the movement of the fluid/clot interface was monitored by confocal laser scanning 
microscopy using double fluorescent tracing (excitation 488 nm/emission 525 nm for tPA-YFP and 
excitation 543 nm/emission 575 nm for fibrin). Images are shown for the 30 min after the application 
of tPA-YFP, scale bar = 50 m. tPA-related fluorescence stains green, whereas the fibrin is red. At 0 
time the edge of the clot was approximately at the top of each field of observation. The numbers 
indicate the relative distance for penetration of tPA-YFP in the clot at 30 min (all values are 
normalized by the mean value of clots with no additives): mean and standard deviation from at least 6 
samples are shown. Asterisk indicates a difference significant at p<0.05 in comparison to control.  
Fig. 5 tPA-induced lysis of clots containing DNA and HIIIS. Plasma clots containing plasminogen 
and the indicated additives were prepared in microplate wells, tPA was applied to the surface, and the 
absorbance was continuously measured at 340 nm. A340 turbidity values were normalized (nA340) as 
described in Materials and methods. Mean curves of 8 measurements from a representative 
experiment are shown. Dotted lines indicate source values of T0.5 and T0.1 parameters shown in the 
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inset (time elapsed until 50% and 90% lysis, respectively). Inset: T0.5 and T0.1 values and standard 
deviation were calculated from mean values of 3 independent experiments with 6-8 replicas each. 
Asterisk indicates a difference significant at p<0.05 test in comparison to control. 
 
Fig. 6 Lysis of clots containing activated neutrophils. Plasma clots containing 5×103/μl 
granulocytes activated by PMA were prepared, tPA ± the indicated additives were added to the surface 
and the absorbance was continuously measured at 340 nm. A340 turbidity values were normalized as 
described in Materials and methods. Mean curves of 8 measurements from a representative 
experiment are shown. Concentrations of additives were: 200 nM for tPA, 1 for APC, 200 IU/ml 
for streptokinase (SK), 400 IU/ml for streptodornase (SD). Inset: macroscopic appearance of well 
contents after 200 min of lysis. Arrows point to web-like floating aggregates remaining after complete 
dissolution of the clots, the structure of which was further examined with SEM as illustrated by the 
inserted electronmicrograph (scale bar=1 m). 
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TABLES 
 
Table 1. Effect of DNA and histones on fibrin fiber diameter of plasma clots. SEM images of 
plasma clots containing the indicated additives and clotted with 16/60 nM thrombin were used for the 
measurement of fiber diameter as previously described (18). The fiber size is reported in nm as median 
and bottom - top quartile values (in brackets) of the theoretical distributions fitted to the measured 
diameter values (4 SEM images per sample with 300 measured diameters in each). Asterisk indicates 
that the parameters of the fitted distributions differ from clots containing no additives at p<0.05. DNA 
was added at 50 g/ml, histone at 250 g/ml concentration. 
Additive None DNA HIIIS DNA + 
HIIIS 
Fiber 
diameter 
(nm) 
 
16 nM thrombin 108 (87-136) 121 (97-150)* 119 (98-146)* 129 (104-159)* 
60 nM thrombin 118 (93-157) 130 (105-159)* 115 (95-141)* 111 (92-134)* 
 
Table 2. Permeability of clots containing DNA and histones. Clots were prepared from either 8 M 
fibrinogen or citrated plasma supplemented with 20 mM CaCl2 and the indicated additives and clotted 
with 16 nM thrombin. The permeability coefficient (Ks) was calculated as described in Materials and 
methods. Ks values and standard deviation were calculated from at least 6 samples originating from 4 
independent experiments. Asterisk indicates p<0.05 in comparison with control containing no 
additives. DNA was added at 50 g/ml, histone at 250 g/ml concentration. 
Additive None DNA HIIIS DNA + 
HIIIS 
Ks 
(10-9 cm2) 
Fibrin 0.62±0.13 0.45±0.08* 2.43±0.81* 2.09±0.38* 
Plasma 6.43±2.58 3.13±1.13* 3.68±0.91* 5.14±1.68 
 
Table 3. Relative lysis times of clots containing activated neutrophils. Clots were prepared from 2-
fold diluted recalcified plasma isolated from the buffy coat fraction of human blood supplemented 
with 3.75 M plasminogen, and PMA-activated neutrophils at 5×103/l. After 4 hours of clotting 
initiated by 16 nM thrombin, 200 nM tPA ± the indicated additives were applied to the surface of the 
clots, and lysis was followed by the continuous measurement of A340. Following evaluation of lysis 
progress curves, T0.5 and T0.1 values (time elapsed until 50% and 10% lysis, respectively) were 
normalized as T0.5/T0.5T and T0.1/T0.1T for each of the experiments, where T0.5T and T0.1T 
represent the average values measured with tPA alone. Values are presented as mean ± standard 
deviation calculated from 11-28 lysis curves originating from 3-5 independent experiments. 
Significant (p<0.05) differences are indicated by * for comparison with lysis in the absence of 
additives, by + for comparison with streptokinase and by # for comparison of the two different 
combinations of streptokinase+streptodornase.   
Additive  None 1  
APC 
200 IU/ml 
streptokinase 
200 IU/ml 
streptokinase 
+400 IU/ml 
streptodornase 
500 IU/ml 
streptokinase 
500 IU/ml 
streptokinase 
+1000 IU/ml 
streptodornase 
T0.5 1.00±0.10 0.99±0.10 0.89±0.11* 0.77±0.13*+ 0.79±0.19* 0.57±0.12*+# 
T0.1 1.00±0.12 0.96±0.08 0.94±0.10 0.89±0.13* 0.89±0.18 0.83±0.12* 
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